FY2025 Earnings Forecast for COYA Issued By Chardan Capital

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at Chardan Capital boosted their FY2025 earnings estimates for shares of Coya Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings per share of ($1.03) for the year, up from their previous forecast of ($1.26). Chardan Capital currently has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Thursday.

Coya Therapeutics Stock Up 5.8 %

Shares of COYA stock opened at $6.89 on Thursday. The firm has a market cap of $115.24 million, a P/E ratio of -10.60 and a beta of 0.31. The company has a 50 day moving average of $6.41 and a 200-day moving average of $6.51. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter worth $401,000. CM Management LLC increased its position in shares of Coya Therapeutics by 11.1% during the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after purchasing an additional 15,941 shares during the last quarter. Jane Street Group LLC purchased a new stake in Coya Therapeutics during the fourth quarter valued at approximately $74,000. Finally, Northern Trust Corp raised its holdings in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after purchasing an additional 3,099 shares during the period. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.